Abstract: Provided are tablet binding compositions for binding cleaning and/or disinfecting formulation components into tablets. The tablet binding compositions are suitable replacements for traditional tablet binder compounds, such as boric acid or zeolites. The tablet binding compositions provided herein can produce tablets of increased hardness at lower compression forces and, when dissolved, yield solutions of increased clarity compared to some traditional binder compounds. Also provided are processes for preparing the tablet binding compositions and methods for formation of tablets containing the tablet binding compositions.

Abstract: The present invention provides edible compositions comprising a compound of the present invention, food products comprising such edible compositions and methods of preparing such food products. The present invention also provides methods of reducing the amount of NaCl in a food product, methods of reducing the sodium intake in a diet, and methods of reducing bitter taste in a food product.

Abstract: The present invention relates to an emulsified hydrogel composition and to a production method therefor, wherein, by incorporating between 20 and 30 percent by weight of a gelling solution and an emulsion obtained by mixing between 45 and 60 percent by weight of an aqueous component and between 15 and 30 percent by weight of an oil component, it is possible to simultaneously provide the skin with an aqueous fraction and an oil fraction, and it is possible to enhance functionality due to the inclusion of a high content of a dermatologically active component dissolved in the oil component.

Abstract: This invention relates to a composition that is mild to the skin containing a cosmetically acceptable oil; water; a cosmetically acceptable emulsifier having an HLB of from about 1 to about 25; and a preservative comprising an organic acid selected from the group consisting of benzoic acid, p-anisic acid, sorbic acid, lactic acid, acetic acid, formic acid, oxalic acid, tartaric acid, salicylic acid and citric acid; wherein said composition has a pH less than 5 and a buffer capacity of between about 0.001 and about 0.039.

Abstract: The invention relates to pharmaceutical compositions that provide sustained-release of a pharmaceutically active compound and to methods of treating or preventing a condition in an animal by administering the pharmaceutical compositions to the animal. When the pharmaceutical compositions are administered to an animal by injection, they form a drug depot that releases the pharmaceutically active compound over time. The pharmaceutical compositions can also be administered orally.

Abstract: A carotenoid-containing composition including: a carotenoid component containing a crystalline carotenoid that is in an amorphous state; a (poly)glycerol fatty acid ester that contains from one to six glycerol units and from one to six fatty acid units and has at least one hydroxyl group resulting from a glycerol unit; a fatty acid ester component which is at least one selected from the group consisting of triesters of glycerol and fatty acids, and esters of alcohols having one hydroxyl group and fatty acids, contains no hydroxyl group in a molecule, and has from 10 to 60 carbon atoms in total; and an antioxidant.

Abstract: The present invention is embodied by a composition capable inducing weight loss in a patient in need thereof.

Abstract: The present invention relates to an improved process for the preparation of unsaturated fatty acids and to a process for the preparation of triglycerides with an increased content of unsaturated fatty acids. The invention relates to the generation of transgenic microorganism, with an increased content of fatty acids, oils or lipids with ?6 double bonds owing to the expression of a moss ?6-desaturase. The invention furthermore relates to transgenic organisms comprising a ?6-desaturase gene, and to the use of unsaturated fatty acids ort of the triglycerides with an increased content if unsaturated fatty acids prepared in the process.

Abstract: Disclosed is 1) a method for greatly increasing the solubility of useful actives in siloxane matrix-forming preparations, and 2) the associated preparations, themselves. Volatilizing coagents are utilized to give novel gels containing heretofore siloxane-insoluble additives.

Abstract: The present invention relates to topical bioadhesive formulations comprising low viscosity, non-liquid crystalline, mixtures of: a) at least one neutral diacyl lipid and/or at least one tocopherol; b) at least one phospholipid; c) at least one biocompatible, oxygen containing, low viscosity organic solvent; wherein at least one bioactive agent is dissolved or dispersed in the low viscosity mixture and wherein the pre-formulation forms, or is capable of forming, at least one liquid crystalline phase structure upon contact with an aqueous fluid. The invention additionally relates to a method of delivery of an active agent comprising administration of a preformulation of the invention, a method of treatment comprising administration of a preformulation of the invention and the use of a preformulation of the invention in a method for the manufacture of a medicament.

Abstract: The following invention relates to a taste enhancer and a method of enhancing taste. The invention relates the use of a cooling enhancing composition which provides cooling enhancement when combined with other cooling compounds.

Abstract: A process is described for preparing acylglycinates of the formula (I) wherein R1 is a linear or branched, saturated alkanoyl group having 6 to 30 carbon atoms, or is a linear or branched, singly or multiply unsaturated alkenoyl group having 6 to 30 carbon atoms, and Q+ is a cation selected from the alkali metals Na+ and K+, the process being characterized in that glycine is reacted with fatty acid chloride R1Cl, wherein R1 possesses the definition stated in formula (I), in water and in the presence of a basic alkali metal compound which yields cations Q+ selected from Na+ and K+, but in the absence of organic solvents, at 25-50° C., and the fraction of fatty acid chloride R1Cl containing unsaturated acyl groups R1 having 18 carbon atoms, based on the total amount of fatty acid chloride used, is greater than or equal to 2.

Abstract: The invention relates to a method for the production of carrier pellets for pharmaceutical active substances. Likewise, the invention relates to such carrier pellets and also to pharmaceutical formulations containing these. The carrier pellets according to the invention are used for transporting and releasing pharmaceutical active substances, in particular in the human body.

Abstract: The present invention related to the use of a pharmaceutical composition which is essentially free of pharmaceutically active agents for the treatment of human skin, especially in the treatment of acne, acne related symptoms, a tetracycline antibiotic responsive acne related disorder, skin disorder caused by a bacteria, and a tetracycline antibiotic responsive sebaceous gland disease, P. acne bacteria associated disorders, and other superficial infections, including skin infections.

Abstract: An amphoteric liposome comprising neutral lipids wherein said neutral lipids are selected from the group comprising cholesterol or mixtures of cholesterol and at least one neutral or zwitterionic lipid and wherein K (neutral) of said mixtures is 0.3 or less. Said amphoteric liposome may encapsulate an active agent, such as nucleic acid therapeutics. Also disclosed are pharmaceutical compositions comprising said amphoteric liposomes as a carrier for the delivery or targeted delivery of active agents or ingredients.

Abstract: The present invention relates to anhydrous or essentially anhydrous compositions intended for topical application on keratinaceous surfaces, wherein the composition includes a) an ionic fluid and b) a thickener. The compositions are advantageous for allowing the ionic fluid to act as the continuous phase of a topical formulation.

Abstract: Drug substances comprising a amine containing pharmaceutically active compound, and at least one of an alditol acetal and an aromatic organic acid as an addition salt or an additive.

Abstract: The present invention provides targeting lipids of structure L100-linker-L101??(CI), where L100 is a lipid, lipophile, alkyl, alkenyl or alkynyl, L101 is a ligand or —CH2CH2(OCH2CH2)pO(CH2)qCH2-ligand, p is 1-1000, and q is 1-20. In addition, the invention provides compositions and methods for the delivery of therapeutic agents to cells. In particular, these include novel lipids and nucleic acid-lipid particles that provide efficient encapsulation of nucleic acids and efficient delivery of the encapsulated nucleic acid to cells in vivo.

Abstract: The invention provides for a method of enhancing immunological responses to an antigen in a vaccine formulation, and for a vaccine formulation that provides for an enhanced immunological response to an antigen. In the method and formulation the antigen is administered with an adjuvant which adjuvant comprises a solution of nitrous oxide gas in a pharmaceutically acceptable carrier solvent for the gas and which adjuvant includes at least one fatty acid or ester or other suitable derivative thereof selected from the group consisting of oleic acid, linoleic acid, alpha-linolenic acid, gamma-linolenic acid, arachidonic acid, eicosapentaenoic acid [C20: 5?3], decosahexaenoic acid [C22: 6?3], ricinoleic acid and derivatives thereof selected from the group consisting of the C1 to C6 alkyl esters thereof, the glycerol-polyethylene glycol esters thereof and the reaction product of hydrogenated natural oils composed largely of ricinoleic acid based oils, such as castor oil with ethylene oxide.

Abstract: The present invention provides a novel method for improving the flavor of a food, drink, pharmaceutical product, oral care product, or the like. One aspect of the present invention is a method for improving the flavor of a food, drink, pharmaceutical product or oral care product, the method including the step of adding 0.1 to 10000 ppb of ?-aminobutyric acid and 0.01 to 10000 ppb of naringenin to the food, drink, pharmaceutical product, or oral care product.

Abstract: The invention relates to composition and related therapeutic methods including at least one antihyperthyroid drug formulated for transdermal administration. Because the formulation is formulated for transdermal administration, the formulation is easier to administer than existing formulations which are administered orally to animals. Issues surrounding transdermal administration versus oral administration have also been resolved allowing the agent to remain stable during storage and retain a high level of efficacy.

Abstract: Silicone containing reactive monomers with hydrophilic end-groups of formula I useful in the manufacture of biocompatible medical devices are disclosed, wherein R1 is H or CH3, a is 0 or 1, p is an integer from 1 to 6, q is an integer from 1 to 3 and for each q, the end groups R51, R52, R53 are independently an alkyl, alkyl ether, trimethylsiloxy group, or a substituted or non-substituted aromatic group and at least one of them has a hydrophilic group attached, preferably to the terminal end of R51, R52, R53, X is O or NR54, where R54 is H or a monovalent alkyl group with 1 to 4 carbons, n is an integer from 1 to 100, R2 and R3 are independently an alkyl, alkyl ether, or a substituted or non-substituted aromatic group, preferred R2 and R3 include methyl, ethyl, and phenyl, L is a divalent linker comprising substituted and unsubstituted alkylene groups having 1-14 carbon atoms, which may be straight or branched, substituted and unsubstituted alkoxy groups having 2-12 carbons, polyethers, oxazolines, and substi

Abstract: The invention relates to microemulsions which comprise, as oil phase, a polysiloxane containing at least one quaternary ammonium group, methods for production thereof and also to the use of such microemulsions.

Abstract: Disclosed herein are food-grade enteric coating compositions designed to release pharmaceutical and/or nutraceutical products at various regions of the intestines, wherein said compositions comprise a film former and a pore former. Also disclosed herein are methods of making and using same.

Abstract: The present invention includes compounds having structural formula (I), or pharmaceutically acceptable salts, solvate, and/or ester thereof. These compounds are useful as sweet flavor modifiers. The present invention also includes compositions comprising the present compounds and methods of enhancing the sweet taste of ingestible compositions. Furthermore, the present invention provides methods for preparing the compounds.

Abstract: A process for producing a compressed solid dosage form containing an active ingredient. The process includes a step of preparing core elements containing the active ingredient. Optionally the core elements are coated with a pharmaceutically acceptable coating layer to form coated pellets. The core elements or pellets are treated with an anti-static agent and compressed with suitable excipients to form the compressed solid dosage form. Preferred anti static agents are starch, microcrystalline cellulose, kaolin, bentonite, silicates, silicon dioxide, cellulose, stearic acid, sodium stearyl fumarate and glyceryl behenate.

Abstract: A method of parenterally administering a composition, the method including parenterally administering to a person a composition including krill oil in an oil-in-water emulsion. A parenterally applicable pharmaceutical composition, including an oil-in-water emulsion including a phospholipid obtained from a marine crustacean.

Abstract: A pharmaceutical composition comprising a lipid component; an amphiphilic emulsifier; and a polar liquid carrier. The lipid component and the amphiphilic emulsifier form free-moving lipid-carrying micelles (LMs) in the polar liquid carrier. The pharmaceutical composition is free of hemoglobin and fluorocarbon and can be used for treating conditions related to lack of blood supply and to raise the blood pressure.

Abstract: An adjuvant composition for modifying the spray properties of an aqueous pesticide composition contains (a) at least one fatty deposition control agent, and (b)(ii) a liquid medium, one or more hydrotropes, and, optionally one or more surfactants, or (b)(ii) one or more surfactants, and adjuvant compositions for modifying the spray properties of an aqueous pesticide composition contains (c) at least one deposition control agent, and (d)(ii) a liquid medium, one or more hydrotropes, and, optionally one or more surfactants, or (d)(ii) one or more surfactants, and use thereof in agricultural applications.

Abstract: Aqueous compositions comprising a) at least one active compound and b) at least one hydrotrope in an amount effective to increase transdermal penetration of the active compound, and methods for increasing bioavailability of active compounds are provided.

Abstract: Compositions and methods for enhancing the absorption of active agents across the mucosa of animal subjects are provided. Methods of administration and appropriate dosage forms are also provided.

Abstract: The present invention relates inter alia to the use of selectively moisture-adjusted tabletting material in the preparation of mechanically stable oral tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing oral tablets.

Abstract: Provided is a composition for preparing emulsion or microemulsion formulations that demonstrates favorable dilution properties without being affected by the solubilities of constituent components. The composition for preparing emulsion or microemulsion formulations contains a component (A): a polyoxyalkylene allyl phenyl ether, polyoxyalkylene aralkyl phenyl ether or polyoxyalkylene aralkenyl phenyl ether, a component (B): a polyoxyalkylene sorbitan alkylate, a component (C): a dialkylsulfosuccinate, and a component (D): an ester ether-based solvent. An emulsion or microemulsion formulation containing the composition is also provided.

Abstract: Disclosed herein are ophthalmic cleaning systems and methods for their use, which comprise an ophthalmic solution and lens case, wherein the solution includes dual disinfectants and the lens case includes silver. When the lens case is combined with the solution according to the system of the present invention, it surprisingly exhibits synergistic activity which results in a faster antimicrobial activity.

Abstract: Novel drug carriers capable of targeted and/or pH dependent release of biologically active agents into selected pH environments including the gastrointestinal (GI), ophthalmic, urinary, or reproductive tracts. Unexpectedly, carriers including free fatty acids (FFA) are able to deliver biologically active agents to various pH environments. Such targeted delivery is tailorable and useful for active agents that are: (a) injurious to the upper GI tract (esophagus, stomach, and duodenum), (b) acid labile, (c) impermeable/insoluble compounds in GI fluids, (d) susceptible to first pass metabolism, and/or (e) cause stomach irritation, upset, or dyspepsia.

Abstract: Methods for extracting an extract of volatile odorous compounds from an organic raw material containing odorous compounds is disclosed. The method includes contacting an organic raw material with dimethyl carbonate, as a solvent, in at least one bath at a temperature of 10° C. to 70° C. A liquid organic phase is obtained that includes the dimethyl carbonate charged with volatile odorous compounds and is collected. If the liquid organic phase comprises an immiscible aqueous phase, decanting occurs to separate the dimethyl carbonate charged with odorous compounds therefrom thereby eliminating the aqueous phase. Next, partially eliminating by evaporation forms a pre-concentrated extract of volatile odorous compounds, which is recovered and if water is present, decanting occurs to eliminate the water. Additionally, concentrating the pre-concentrated extract of volatile odorous compounds by evaporation is performed to obtain the extract of volatile odorous compounds.

Abstract: Carrier compounds and compositions therewith which are useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a ?-tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: The invention provides a particulate composition adapted for forming a bone graft substitute cement upon mixing with an aqueous solution, including i) a calcium sulfate hemihydrate powder having a bimodal particle distribution and a median particle size of about 5 to about 20 microns, wherein the calcium sulfate hemihydrate is present at a concentration of at least about 70 weight percent based on the total weight of the particulate composition; ii) a monocalcium phosphate monohydrate powder; and iii) a ?-tricalcium phosphate powder having a median particle size of less than about 20 microns. Bone graft substitute cements made therefrom, a bone graft substitute kit comprising the particulate composition, methods of making and using the particulate composition, and articles made from the bone graft substitute cement are also provided.

Abstract: In its several embodiments, this invention discloses a pharmaceutical formulation comprising at least one antineoplastic agent or a pharmaceutically acceptable salt thereof, and at least one dissolution enhancing agent sufficient to substantially dissolve said at least one antineoplastic agent in at least one aqueous diluent, wherein said dissolution enhancing agent is urea, L-histidine, L-threonine, L-asparagine, L-serine, L-glutamine or mixtures thereof; a lyophilized powder comprising said pharmaceutical formulation, and articles of manufacture thereof.

Abstract: An emulsion-type composition comprising a fatty continuous phase is presented, preferably of water-in-oil type, said composition including at least one polyglyceryl polyricinoleate, at least one polyol and at least one volatile linear alkane. It also relates to the use of such a composition for conferring on said composition improved comfort on application and/or improved stability.

Abstract: A stabilized oil-in-water seed treatment formulation having superior handling characteristics.

Abstract: Disclosed is an external preparation composition having good transdermal absorbability. An external preparation composition having excellent transdermal absorbability can be produced by dissolving a medicinal substance or a salt thereof in a fatty acid-based ionic liquid to form a composite ionic composition of the medicinal substance. The external preparation composition can be used as a liquid preparation, an ointment, a cream, a plaster or the like, and enables to provide a preparation having excellent transdermal absorbability.

Abstract: The present disclosure relates generally to compositions for cosmetic or pharmaceutical application. The compositions include a carrier and rheology modulators.

Abstract: A variety of betaine esters, including dialkylaminoalkyl cocoate betaines and dialkylaminoalkyl hydrogenated cocoate betaines are disclosed. These betaines can be advantageously prepared in high yield and purity by a three-step transiterification chemoenzymatic process or a two-step direct esterficiation chemoenzymatic process. These betaine esters have excellent surfactant properties.

Abstract: The problem of the present invention is provision of a cleansing composition providing good amount and good quality of lather. Using a particular alkenoic acid or a salt thereof, the above-mentioned problem can be solved. In addition, the cleansing composition provided by the present invention is stable in various formulations and also useful for rough skin and damaged hair.

Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Abstract: An aqueous disinfecting solution having a pH from about 0.5 to about 6 and consisting essentially of hydrogen peroxide in a concentration from about 0.05 to about 8 w/w % of the total solution; at least one anionic surfactant in a concentration from about 0.02 to about 8 w/w % of the total solution, selected from sulfonated C12 to C22 carboxylic acids and alkali metal, ammonium, calcium and magnesium salts thereof; naphthalene sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; C8 to C22 alkyl sulfonic acids and alkali metal, ammonium, calcium and magnesium salts thereof; and alkyl or alkenyl esters or diesters of sulfosuccinic acids in which the alkyl or alkenyl groups independently contain from six to eighteen carbon atoms and alkali metal, ammonium, calcium and magnesium salts thereof; and benzyl alcohol in a concentration from about 0.1 to about 10 w/w % of the solution.

Abstract: A personal care composition includes at least one end-functionalized ionic silicone and at least one film-forming agent.

Abstract: The present invention is to provide a vesicle composition comprising the following components (A), (B) and (C): (A) 0.0001 to 20 mass % of an organic acid represented by general formula (1): wherein R1 represents a natural sterin having a single hydroxy group or a hydrogenated product thereof or a residue which remains after a hydrogen atom is removed from the hydroxy group of bile acid, R2 represents a divalent hydrocarbon group having 1 to 24 carbon atoms, M represents a hydrogen atom, an alkali metal, an alkali earth metal, ammonium, an alkanolammonium having 2 to 9 carbon atoms in total, an alkylammonium or alkenylammonium having 1 to 22 carbon atoms in total, pyridinium substituted with an alkyl group or alkenyl group having 1 to 18 carbon atoms or a basic amino acid, (B) 0.0001 to 10 mass % of a sphingosine, and (C) water, and having a pH of 2 to 11.